Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
123457989
发表于 2024-12-10 16:19:27
1133
0
0
On December 10th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA®) Approved by the National Medical Products Administration (NMPA) of China, the combination of radiotherapy and chemotherapy is used for the treatment of stage III-IVA cervical cancer patients in the International Federation of Obstetrics and Gynecology (FIGO) 2014. The approval of this new indication is based on data from the global phase III clinical trial KEYNOTE-A18.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Merck PD-1 inhibitor CRDA approved as a new indication for melanoma treatment in China
- Lilly: The first and only non covalent (reversible) BTK inhibitor, Jeparil, has been approved in China
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Sanofi's BTK inhibitor is declared for market in China
